Douglas Miehm
Stock Analyst at RBC Capital
(3.67)
# 832
Out of 5,127 analysts
59
Total ratings
58.7%
Success rate
7.24%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $234 → $235 | $200.07 | +17.46% | 8 | Dec 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $17.30 | +9.83% | 14 | Nov 14, 2025 | |
| MNKD MannKind | Maintains: Outperform | $8 → $7.5 | $6.01 | +24.79% | 4 | Nov 11, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $15.33 | -2.15% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $7.77 | +28.70% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.99 | +404.24% | 1 | Mar 10, 2025 |
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $234 → $235
Current: $200.07
Upside: +17.46%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $17.30
Upside: +9.83%
MannKind
Nov 11, 2025
Maintains: Outperform
Price Target: $8 → $7.5
Current: $6.01
Upside: +24.79%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $15.33
Upside: -2.15%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $7.77
Upside: +28.70%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.99
Upside: +404.24%